EUVIMEDEUVIMED entdecken
Crossref

Interim study results of follow-up optimization after completed therapy of head and neck cancer

Felix Böhm, Marko Vujic, Matthias Brand, Adrian von Witzleben, Jens Greve, Simon Laban, Anna-Katharina Rohlfs, Thomas Hoffmann, Patrick J. Schuler

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S197

DOI: 10.1055/s-0044-1784635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Felix Böhm und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Our post-treatment optimization study compares oncological standard follow-up (control arm) with alternating tumor surveillance through certified head and neck tumor centers and office-based ENT specialists (study arm).

Methods

Patients were randomized into the two study arms during the initial follow-up examination following the completion of therapy for squamous cell carcinoma in the head and neck region. A 48-month follow-up period was evaluated concerning disease-free survival and recurrence diagnosis.

Results

So far, 140 patients (55 study arm vs. 85 control arm) have been included. Among these, 29 recurrences occurred. The mean follow-up period for participants was 27.7 months. The mean disease-free survival (DFS) was 8.7 months in the study arm versus 14.4 months in the control arm. The Log-Rank test has not shown a statistically significant difference between the study arms (p=0.69) thus far. Over half of the recurrences (55%) were detected through follow-up examinations at the tumor center. 31% of recurrences were identified by tumor-associated newly emerged symptoms, and only 7% through annual restaging via imaging. An additional 7% were diagnosed by colleagues from other medical specialties.

Conclusion

Modified follow-up involving office-based ENT specialists and head and neck tumor centers appears to be equivalent in terms of recurrence detection time, as expressed by DFS, and often offers an improved quality of life. Long-term results regarding overall survival, considering the current mean follow-up period of 27.7 months for participants, need to be awaited for a final interpretation. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Böhm, F., Vujic, M., Brand, M., Witzleben, A. V., Greve, J., Laban, S., Rohlfs, A., Hoffmann, T., & Schuler, P. J. (2024). Interim study results of follow-up optimization after completed therapy of head and neck cancer. Laryngo-Rhino-Otologie, 103(S 02 S 02), S197. https://doi.org/10.1055/s-0044-1784635

Vancouver

Böhm F, Vujic M, Brand M, Witzleben AV, Greve J, Laban S, et al. Interim study results of follow-up optimization after completed therapy of head and neck cancer. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S197. doi:10.1055/s-0044-1784635

BibTeX
@article{Bhm2024,
  author = {Böhm, Felix and Vujic, Marko and Brand, Matthias and Witzleben, Adrian von and Greve, Jens and Laban, Simon and Rohlfs, Anna-Katharina and Hoffmann, Thomas and Schuler, Patrick J.},
  title = {Interim study results of follow-up optimization after completed therapy of head and neck cancer},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S197},
  doi = {10.1055/s-0044-1784635}
}
Kostenlos starten →